stoxline Quote Chart Rank Option Currency Glossary
Oncorus, Inc. (ONCR)
0.126  -0.004 (-3.08%)    12-29 14:55
Open: 0.1268
High: 0.2
Volume: 135,947
Pre. Close: 0.13
Low: 0.125
Market Cap: 3(M)
Technical analysis
2024-01-12 4:53:03 PM
Short term     
Mid term     
Targets 6-month :  0.23 1-year :  0.27
Resists First :  0.2 Second :  0.23
Pivot price 0.03
Supports First :  0.08 Second :  0
MAs MA(5) :  0.07 MA(20) :  0.03
MA(100) :  0.02 MA(250) :  0.16
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  86.4 D(3) :  70.8
RSI RSI(14): 89.9
52-week High :  0.46 Low :  0
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ONCR ] has closed above the upper band by 3.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 801.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.2 - 0.2 0.2 - 0.2
Low: 0.12 - 0.12 0.12 - 0.12
Close: 0.12 - 0.13 0.13 - 0.13
Company Description

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Headline News

Mon, 05 Jun 2023
Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat - Yahoo Finance

Fri, 02 Jun 2023
Facing bankruptcy, Oncorus lays off 'substantially' all staff - Fierce Biotech

Wed, 30 Nov 2022
Oncorus Pulls Plug On Phase 1 Candidate, Lays Off 20% Of Its Workforce - Yahoo Finance

Wed, 30 Nov 2022
Oncorus lays off 15% of workforce, drops solid tumor prospect - Fierce Biotech

Fri, 07 Oct 2022
Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer -

Wed, 22 Sep 2021
DPS Group Tapped by Oncorus to Design GMP Clinical Manufacturing Facility - Boston Real Estate Times

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 26 (M)
Shares Float 24 (M)
Held by Insiders 12.1 (%)
Held by Institutions 0 (%)
Shares Short 448 (K)
Shares Short P.Month 164 (K)
Stock Financials
EPS -3.49
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.19
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -32.3 %
Return on Equity (ttm) -124.6 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.68
Qtrly Earnings Growth 0 %
Operating Cash Flow -56 (M)
Levered Free Cash Flow -54 (M)
Stock Valuations
PE Ratio -0.04
PEG Ratio 0
Price to Book value 0.1
Price to Sales 0
Price to Cash Flow -0.06
Stock Dividends
Dividend 0.14
Forward Dividend 0
Dividend Yield 111.1%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android